China's first mRNA vaccine phase III trial in the race to produce viable COVID-19 vaccines will begin soon. And it will be conducted using the Viedoc eClinical suite. Viedoc has been chosen as the go-to tool for this important and high-profile phase III study conducted in 38 sites and 30 000 subjects. Walvax Bio aims to set into production the first mRNA vaccine out of China, making this study a highly prestigious study.
"We are proud to be working with Walvax Biotechnology on critically important trials such as this, which are vital, not only to medical science but to the health of our global community," said Viedoc Technologies Business Development Manager China. "This new partnership we've formed will allow us to accelerate the research of this critical clinical study. Trials like these are the very reason we have offered reduced rates in COVID-19 research. The faster we can help complete their vital Phase III, the better it will be for the health of the world."
Walvax Biotechnology is pleased to collaborate with Viedoc. "Viedoc's unified eClinical suite is a critical component in the success of our efforts to develop a safe and effective vaccine against COVID-19." Says Walvax Biotechnology.
Walvax needed an eClinical suite that could match their demands of reliability, speed, and adaptivity — a system they could rely upon was vital — Walvax chose Viedoc.
Find out how Viedoc can accelerate your trial. Contact us today.
Enjoy your trial!
Walvax Biotechnology was founded in 2001. It is a modern biopharmaceutical enterprise specialized in the research and development, production and sales of biological drugs such as vaccines and blood products. It is a highly recognized high-tech enterprise in China. The company traded in Shenzhen Stock Exchange in November 2010.
"The system is incredibly robust and is very user friendly, both to sponsor level satff, as well as site staff who remotely enter data."